The Brief
For many people living with schizophrenia, daily oral medication can be difficult to maintain consistently. Missed doses can increase the risk of symptom return, and the daily routine itself can feel like a constant reminder of treatment.
INVEGA SUSTENNA from Johnson & Johnson, a once-monthly long-acting injectable administered by a healthcare professional, needed to reframe treatment as a path to steadier support. The goal was to help patients and caregivers understand that there are options beyond a daily pill, and encourage informed conversations with healthcare providers.
The Results
We created a film that told the story of the daily pressure behind a daily pill. The film held that tension with the sensitivity needed for the disease. We introduced INVEGA SUSTENNA as a once-monthly option for people who may benefit from a steadier treatment. The work helped drive awareness and encouraged real conversations between patients, caregivers, and providers about whether a long-acting injectable could be the right fit and potentially live-saving.
Stability doesn’t have to be
a tightrope.
